EU Hat Trick For Bluebird’s Beta-Thalassemia Gene Therapy
Executive Summary
bluebird bio is set to enter the EU market with the first gene therapy for transfusion-dependent β-thalassemia, after the European Medicines Agency reviewed its product in record time. Bluebird believes that the agency’s Priority Medicines (PRIME) and adaptive pathways programs have been instrumental in smoothing its path.
You may also be interested in...
Coronavirus Update: R&D Starts, Product Delays, Continuing Collaboration
In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments.
Keeping Track: US FDA Okays BMS’ Zeposia In MS, Nixes Lilly/BI’s Empagliflozin For Type 1 Diabetes
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
New EU Market Hopefuls Await Their Fate; EMA Re-Adopting Zynteglo Opinion
Sponsors of a raft of new products will find out this week if the European Medicines Agency’s medicines evaluation committee, the CHMP, is convinced the therapies are ready for marketing.